Generics in rheumatological pharmacotherapy;Generika in der rheumatologischen pharmakotherapie

Aktuelle Rheumatologie

Volumn 28, Issue 3, 2003, Pages 138-143

  Petersen, Karl Uwe ^a  

^a Pharmakologe und Toxikologe   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; DICLOFENAC; GENERIC DRUG; GOLD SALT; HYDROXYCHLOROQUINE; IBUPROFEN; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PENICILLAMINE; SALAZOSULFAPYRIDINE;

ARTICLE; BIOEQUIVALENCE; DRUG APPROVAL; DRUG BIOAVAILABILITY; GERMANY; GOLD THERAPY; RHEUMATOLOGY;

EID: 0038104004     PISSN: 0341051X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-40443     Document Type: Article

References (43)

1. Abendroth. Persönliche Mitteilung
2. Barone JA. Comparative potency and dissolution performance of internationally available piroxicam products. Pharmacoeconomics 1992; 1 (Suppl 1): 49-52
3. Blume H, Schug B, Cordes G et al. Qualität von Omeprazol-Präparaten. Dt Apoth Z 2001; 141: 73-78
4. Bochner F, Somogyi AA, Wilson KM. Bioinequivalence of four 100 mg oral aspirin formulations in healthy volunteers. Clin Pharmacokinet 1991; 21: 394-399
5. Carter BL, Noyes MA, Demmler RW. Differences in serum concentrations of and responses to generic verapamil in the elderly. Pharmacotherapy 1993; 13: 359-368
6. Cicloral. Standardinformation für Krankenhausapotheker 2001
7. Copeland PM. Two cases of therapeutic failure associated with levothyroxine brand interchange. Ann Pharmacother 1995; 29: 482-485
8. Corpetti G, Rosignoli MT, Dionisio P. Comparative bioavailability study of two oral formulations of ibuprofen. Arzneimittelforschung 1998; 48: 392-395
9. Dong BJ, Brown CH. Hypothyroidism resulting from generic levothyroxine failure. J Am Board Fam Pract 1991; 4: 167-170
10. Gleiter CH, Gundert-Remy U. Bioinequivalence and drug toxicity. How great is the problem and what can be done? Drug Saf 1994; 11: 1-6
11. Graffner C, Josefsson K, Stockman O. Intra- and intersubject variation of erythromycin absorption from single-unit and multiple-unit enteric-coated products. Biopharm Drug Dispos 1986; 7: 163-171
12. Haroldson JA, Somerville KT, Carlson S et al. A retrospective assessment of safety, efficacy, and pharmacoeconomics of generic azathioprine in heart-transplant recipients. J Heart Lung Transplant 2001; 20: 372-374
13. Health Canada HC: Expert Advisory Committee Working Group. Expert advisory committee on bioavailability and bioequivalence (http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advcomm/eac/ bb/minutes/2001-11-15_e.pdf; besucht am 30.12.2002) 2001
14. Henney JE. From the food and drug administration: nationwide recall of SangCya oral solution. JAMA 2000; 284: 1234
15. Jochsberger T, Kirschenbaum H, Gaynor H et al. Effect of brand on the serum level of aspirin. Drug Intell Clin Pharm 1983; 17: 550-55
16. Johnston A. Vortrag
17. Kluznik JC, Walbek NH, Farnsworth MG et al. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatr 2001; 62 (Suppl 5): 14-17
18. Lam YW, Ereshefsky L, Toney GB et al. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry 2001; 62 (Suppl 5): 18-22
19. Manorot M, Rojanasathien N, Louthrenoo W et al. Comparative studies of quality and bioavailability of methotrexate in Thai patients with rheumatoid arthritis. J Med Assoc Thai 1998; 81: 978-985
20. Meyer MC, Straughn AB, Jarvi EJ et al. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm Res 1992; 9: 1612-1616
21. Möller H, Potthast H. Biopharmazeutische Charakterisierung von Arzneistoffen und Fertigarzneimitteln. Pharm Z 2001(http://www.pharmazeutische-zeitung.de/pza/1999-20/pharm5.htm; besucht am 29.12.2002)
22. Mofsen R, Balter J. Case reports of the reemergence of psychotic symptoms after conversion from brand-name clozapine to a generic formulation. Clin Ther 2001; 23: 1720-1731
23. National Kidney Foundation. Drug Substitution in Transplantation. Recommendations to the Health Care Community 1998 (http://www.transweb.org/reference/articles/drugs/drug_substitution.htm, besucht am 30.12.2002)
24. Navarro MA, Raei N, Torres F et al. Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration. Gastroenterol Hepatol 1998; 21: 63-70
25. Olling M, Mensinga TT, Barends DM et al. Bioavailability of carbamazepine from four different products and the occurrence of side effects. Biopharm Drug Dispos 1999; 20: 19-28
26. Opelz G. Newsletter der CTS Collaborative Transplant Study 2001 (http://www.ctstransplant.org/public/literature/newsletters/2001/gif/ 2001 - 1.html, besucht am 30.12.02)
27. Peran S, Garriga MJ, Morreale de Escobar G et al. Increase in plasma thyrotropin levels in hypothyroid patients during treatment due to a defect in the commercial preparation. J Clin Endocrinol Metab 1997; 82: 3192-3195
28. Petersen KU. Freisetzung von Omeprazol aus Kapsel-Generika in vitro. Der Deutsche Apotheker 1999; 51: 213-217
29. Petersen KU. Originale und Nachahmer. Med Klinik 2000; 95: 26-30
30. Petersen KU. In vitro release of felodipine from original brand and generic products. Arzneimittelforschung 2003; 53: 40-43
31. Potthast H, Mircioiu I, Bastian B et al. Biopharmazeutische Charakterisierung von Diclofenac-Präparaten. Pharm Z 2001 (http://www.pharmazeutische-zeitung.de/pza/2001-45/pharm4.htm; besucht am 29.12.2002)
32. Potthast H, Winter S, Bastian B et al. Ibuprofen-Präparate im Vergleich. Pharm Z 2002(http://www.pharmazeutische-zeitung.de/pza/2002 - 19/pharm7.htm; besucht am 29.12.2002)
33. Rambeck B, Boenigk HE, Stenzel E. Bioavailability of three phenytoin preparations in healthy subjects and in epileptics. Eur J Clin Pharmacol 1977; 12: 285-290
34. Randinitis EJ, Sedman AJ, Welling PG et al. Effect of a high-fat meal on the bioavailability of a polymer-coated erythromycin particle tablet formulation. J Clin Pharmacol 1989; 29: 79-84
35. Reiffell D. Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. Am J Cardiol 2000; 85: 46D-52D
36. Sindhi R, Allaert J, Gladding D et al. Cytokines and cell surface receptors as target end points of immunosuppression wit cyclosporine A. J Interferon Cytokine Res 2001; 21: 507-514
37. Soryal I, Richens A. Bioavailability and dissolution of proprietary and generic formulations of phenytoin. J Neurol Neurosurg Psychiatry 1992; 55: 688-691
38. Tanaka E. Gender-related differences and their clinical significance. J Clin Pharm Ther 1999; 24: 339-346
39. Teresi ME, Riggs CE, Webster PM et al. Bioequivalence of two methotrexate formulations in psoriatic and cancer patients. Ann Pharmacother 1993; 27: 1434-1438
40. Van Gelderen ME, Olling M, Barends DM et al. The bioavailability of diclofenac from enteric coated products in healthy volunteers with normal and artificially decreased gastric acidity. Biopharm Drug Dispos 1994; 15: 775-788
41. Waldman SA, Morganroth J. Effects of food on the bioequivalence of different verapamil sustained-release formulations. J Clin Pharmacol 1995; 35: 163-169
42. Welage LS, Kirking DM, Ascione FJ et al. Understanding the scientific issues embedded in the generic drug approval process. J Am Pharm Assoc 2001; 41: 856-867 (http://www.aphanet.org/JAPhA/novdec01pdfs/welage%20.pdf; besucht am 30.12.2002)
43. Wilder BJ, Leppik I, Hietpas TJ et al. Effect of food on absorption of Dilantin Kapseals and Mylan extended phenytoin sodium capsules. Neurology 2001; 57: 582-589